Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $1.1 million.

  • Ligand Pharmaceuticals' Change in Accured Expenses fell 5092.05% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 8278.75%. This contributed to the annual value of $13.9 million for FY2024, which is 39555.7% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Change in Accured Expenses of $1.1 million as of Q3 2025, which was down 5092.05% from -$407000.0 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Change in Accured Expenses peaked at $11.3 million during Q4 2024, and registered a low of -$4.8 million during Q2 2021.
  • In the last 5 years, Ligand Pharmaceuticals' Change in Accured Expenses had a median value of -$407000.0 in 2025 and averaged $379263.2.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Change in Accured Expenses crashed by 70503.14% in 2021, and later skyrocketed by 46056.74% in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Change in Accured Expenses stood at $6.4 million in 2021, then tumbled by 145.54% to -$2.9 million in 2022, then soared by 193.94% to $2.8 million in 2023, then soared by 309.36% to $11.3 million in 2024, then tumbled by 90.32% to $1.1 million in 2025.
  • Its Change in Accured Expenses was $1.1 million in Q3 2025, compared to -$407000.0 in Q2 2025 and -$2.1 million in Q1 2025.